Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

861
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
861
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

646
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
646
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

987
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
987
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

107
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
107
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.0K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

686
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
686

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence, Clinical Correlates, and Functional Implications of Vestibular Symptoms in Patients With Migraine.

Neurology·2025
Same author

Cerebral Amyloid Angiopathy-Related Inflammation.

Acta neurologica Taiwanica·2025
Same author

Light Therapy in Chronic Migraine.

Current pain and headache reports·2024
Same author

Focused Update on Migraine and Vertigo Comorbidity.

Current pain and headache reports·2024
Same author

Recurrent hemichorea with different etiologies in one patient.

Oxford medical case reports·2023
Same author

Posterior Cingulate Cortex Network Predicts Alzheimer's Disease Progression.

Frontiers in aging neuroscience·2021
Same journal

Preface.

Progress in brain research·2025
Same journal

Mindfulness and meditation: Promoting emotional and cognitive health.

Progress in brain research·2025
Same journal

Cognitive stimulation enhancing memory and mental function.

Progress in brain research·2025
Same journal

The science behind non-pharmacological interventions.

Progress in brain research·2025
Same journal

Technology-assisted interventions for neuropsychiatric disorders.

Progress in brain research·2025
Same journal

Ethical consideration in non-pharmacological treatments for neuropsychiatric disorders.

Progress in brain research·2025
See all related articles

Related Experiment Video

Updated: Dec 7, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K

Update in migraine preventive treatment.

Tzu-Hsien Lai1, Tzu-Chou Huang2

  • 1Department of Neurology, Far Eastern Memorial Hospital, New Taipei, Taiwan; Department of Neurology, National Yang-Ming University School of Medicine, Taipei, Taiwan.

Progress in Brain Research
|October 3, 2020
PubMed
Summary
This summary is machine-generated.

Migraine prevention is key to reducing disability and costs. New calcitonin-gene related peptide (CGRP) therapies offer effective options, but patient-specific factors guide treatment choices.

Keywords:
Chronic migraineEpisodic migrainePrevention

More Related Videos

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.2K

Related Experiment Videos

Last Updated: Dec 7, 2025

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

18.6K
Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders
05:49

Author Spotlight: Deciphering Electrical Networks Behind Complex Brain Activities and Disorders

Published on: November 1, 2024

1.1K
Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache
05:40

Dural Stimulation and Periorbital von Frey Testing in Mice As a Preclinical Model of Headache

Published on: July 29, 2021

9.2K

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Migraine is a common neurological disorder causing significant disability and socioeconomic burden.
  • Preventive treatments can decrease headache frequency and improve quality of life, yet remain underutilized.

Purpose of the Study:

  • To review the current landscape of migraine preventive therapies.
  • To highlight the emerging role of calcitonin-gene related peptide (CGRP) pathway inhibitors.
  • To discuss factors influencing treatment selection for individual patients.

Main Methods:

  • Literature review of migraine pathophysiology and treatment options.
  • Analysis of clinical evidence for CGRP monoclonal antibodies and antagonists.
  • Consideration of patient-specific factors in treatment decisions.

Main Results:

  • Significant advancements have been made with CGRP monoclonal antibodies and antagonists.
  • These novel therapies offer effective migraine prevention.
  • Treatment selection requires careful consideration of efficacy, side effects, comorbidities, and patient preferences.

Conclusions:

  • CGRP-targeted therapies represent a major advance in migraine prevention.
  • Personalized treatment approaches are essential for optimizing outcomes in migraine management.
  • Addressing underutilization of preventive therapies remains a clinical priority.